Health Care·Pharmaceuticals·$4.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.53 | N/A | -2.51% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.53 | N/A | -2.51% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a cautious optimism regarding their ongoing projects. They emphasized their commitment to advancing their drug development despite current challenges.
Management highlighted ongoing development efforts and future potential.
They acknowledged the challenges faced but expressed confidence in their pipeline.
Crinetics Pharmaceuticals reported a loss that was slightly worse than expected, but the stock rose by 8.83%. This increase may reflect investor optimism about the company's future projects and management's positive outlook despite the loss. The lack of revenue data and guidance may leave some investors cautious, but the stock's reaction indicates a belief in the company's potential.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
DISNEY WALT CO
Aug 4, 2020